1351961-59-5

Basic information

• Product Name: 7-[(4-Methoxyphenyl)Methyl]-5-Methyl-2H-pyrazolo[3,4-d]pyriMidine-4,6(5H,7H)-dione
• Synonyms: 7-[(4-Methoxyphenyl)Methyl]-5-Methyl-2H-pyrazolo[3,4-d]pyriMidine-4,6(5H,7H)-dione;7-(4-Methoxybenzyl)-5-Methyl-2H-Pyrazolo[3,4-D]Pyrimidine-4,6(5H,7H)-Dione;7-(4-Methoxybenzyl)-5-Methyl-2H-Pyrazolo[3,4-D]Pyrimidine-4,6(5H,7H)-Dione(WXC01631)
• CAS NO: 1351961-59-5
• Molecular Formula: C₁₄H₁₄N₄O₃
• Molecular Weight: 285.27802
• Product Categories: Aromatics, Nucleotides, Bases & Related Reagents
• Mol File: 1351961-59-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-[(4-Methoxyphenyl)Methyl]-5-Methyl-2H-pyrazolo[3,4-d]pyriMidine-4,6(5H,7H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[(4-Methoxyphenyl)Methyl]-5-Methyl-2H-pyrazolo[3,4-d]pyriMidine-4,6(5H,7H)-dione(1351961-59-5)
• EPA Substance Registry System: 7-[(4-Methoxyphenyl)Methyl]-5-Methyl-2H-pyrazolo[3,4-d]pyriMidine-4,6(5H,7H)-dione(1351961-59-5)

Safety Data

• Hazardous Substances Data: 1351961-59-5(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1351961-59-5 differently. You can refer to the following data:
1. 7-[(4-Methoxyphenyl)Methyl]-5-Methyl-2H-pyrazolo[3,4-d]pyriMidine-4,6(5H,7H)-dione is an intermediate in the synthesis of PDE-1 inhibitors, used in therapy for parkinson’s disease, depression and narcolepsy.
2. An intermediate in the synthesis of PDE-1 inhibitors, used in therapy for parkinson’s disease, depression and narcolepsy.

Upstream product

• 916764-90-4 6-hydrazinyl-1-(4-methoxybenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1520918-63-1 2-(4-(6-fluoropyridin-2-yl)benzyl)-7-(4-methoxybenzyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 
• 916764-95-9 2-(biphenyl-4-ylmethyl)-6-(1-hydroxy-2-methylpropan-2ylamino)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 916764-93-7 2-(biphenyl-4-ylmethyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 
• 916764-94-8 2-(biphenyl-4-ylmethyl)-6-chloro-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 36074-55-2 2-benzyl-5-methyl-2,7-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4,6(5H)-dione 

Relevant articles and documents

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases

A diverse set of 3-aminopyrazolo[3,4-d]pyrimidinones was designed and synthesized. The structure-activity relationships of these polycyclic compounds as phosphodiesterase 1 (PDE1) inhibitors were studied along with their physicochemical and pharmacokinetic properties. Systematic optimizations of this novel scaffold culminated in the identification of a clinical candidate, (6aR,9aS)-2-(4-(6-fluoropyridin-2-yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4-(2H)-one phosphate (ITI-214), which exhibited picomolar inhibitory potency for PDE1, demonstrated excellent selectivity against all other PDE families and showed good efficacy in vivo. Currently, this investigational new drug is in Phase I clinical development and being considered for the treatment of several indications including cognitive deficits associated with schizophrenia and Alzheimer's disease, movement disorders, attention deficit and hyperactivity disorders, and other central nervous system (CNS) and non-CNS disorders.

SALT CRYSTALS

The present invention relates to acid addition salt and salt crystals of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, composition comprising the same and the method of making and using such salt and crystals.